GGT and Uric Acid to Predict Gestational Diabetes Mellitus
Key facts
- Who runs it
- Mount Carmel Health System
- Where
- Columbus, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- 21 Jun 2021
- Ended
- 31 Dec 2024
- Type of study
- Observational
- Treatments tested
- GGT/Uric Acid
- Record updated
- 6 June 2025
- Why it stopped
- Principal Investigator left the institution.
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Pregnant women between > 9 weeks and < 14.0 weeks gestation
Who cannot take part
- Known history of or current diagnosis of type I or type II diabetes mellitus
- Known liver disease
- Known kidney disease
- Known history of or current diagnosis of gout
- Known history of alcoholism or current alcohol use
- < 18 years of age
- Multiple gestation
Where in United States
- Mount Carmel Health SystemColumbus, United States
About the trial
What the trial wants to find out
Gestational Diabetes Mellitus (GDM) is a common metabolic complication of pregnancy defined as new onset hyperglycemia during gestation. GDM conveys significant risk of morbidity and mortality for both mother and infant. An estimated 268,900 infants were born to mothers with GDM in the USA, accounting for approximately 6.9% of births. Although individual correlations have been found between elevated GGT and uric acid levels and later development of GDM, no research has established and validated combined criteria for GGT and uric acid levels that would lead to their use in identifying women at high risk of GDM in the first trimester.
Read full original descriptionShow less
Central Hypothesis: Serum GGT and serum uric acid collected between >9-14.0 weeks gestation will be significantly elevated in women who later develop GDM compared to those who do not. Combined analysis of serum uric acid and GGT levels within the first trimester allows for accurate prediction of the development of GDM.
Study population includes women between 9-14 weeks gestation undergoing a standard first trimester blood draw. Additional blood will be drawn during the standard blood draw to assess GGT and uric acid levels. Research participants will be tracked afterwards to determine whether they tested positive for gestational diabetes during the standard testing process which typically occurs at 24-28 weeks gestation. The data will then be analyzed to estimate the sensitivity, specificity, positive and negative predictive values of the first trimester GGT and uric acid tests. The GGT and uric acid levels which maximize the area under the receiver-operator characteristic curve will be identified.
The group in the trial
- First Trimester Prenatal Visit
Women attending an initial first trimester prenatal visit who will be undergoing a standard blood draw.
Treatment: GGT/Uric Acid
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Association of Elevated Serum Gamma Glutamyl Transferase (GGT) and Uric Acid at 9-14 Weeks Gestation With the Development of Gestational Diabetes Mellitus (GDM)
- Record updated
- 6 June 2025